Everolimus (Afinitor®, Zortress®)

Class: mTOR inhibitor (mammalian target of rapamycin)

• Mechanism: Inhibits mTOR → suppresses cell proliferation and angiogenesis
• Indications:
  • RCC (post-VEGF therapy)
  • Neuroendocrine tumors, breast cancer (HR+/HER2−), TSC-related tumors
• Dose (RCC): 10 mg orally once daily
• Key Toxicities:
  • Stomatitis, rash, non-infectious pneumonitis
  • Hyperglycemia, hyperlipidemia, cytopenias
  • Immunosuppression → risk of infection
• Monitoring:
  • CBC, fasting glucose, lipids, LFTs, pulmonary symptoms
  • CYP3A4 interactions (dose adjustments may be needed)